These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 9279289)

  • 41. Danaparoid is not a low-molecular-weight heparin.
    Nicholson CD; Meuleman DG; Magnani HN; Egberts JF; Leibowitz DA; Spinler SA; Cziraky MJ
    Am J Hosp Pharm; 1994 Aug; 51(16):2049-50. PubMed ID: 7526686
    [No Abstract]   [Full Text] [Related]  

  • 42. Heparin versus danaparoid in off-pump coronary bypass grafting: results of a prospective randomized clinical trial.
    Carrier M; Robitaille D; Perrault LP; Pellerin M; Pagé P; Cartier R; Bouchard D
    J Thorac Cardiovasc Surg; 2003 Feb; 125(2):325-9. PubMed ID: 12579101
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Peri-operative anticoagulation with danaparoid for a patient with Budd-Chiari syndrome and heparin-induced thrombocytopenia].
    Brémaud M; De Maistre E; Junke E; Guerci A; Lalot JM; Longrois D; Lecompte T; Meistelman C
    Ann Fr Anesth Reanim; 2004 Feb; 23(1):50-5. PubMed ID: 14980323
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lipoprotein lipase in hemodialysis patients: indications that low molecular weight heparin depletes functional stores, despite low plasma levels of the enzyme.
    Näsström B; Stegmayr B; Olivecrona G; Olivecrona T
    BMC Nephrol; 2004 Nov; 5():17. PubMed ID: 15527497
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Quantification of chondroitin sulfate and dermatan sulfate in danaparoid sodium by (1)H NMR spectroscopy and PLS regression.
    Ustün B; Sanders KB; Dani P; Kellenbach ER
    Anal Bioanal Chem; 2011 Jan; 399(2):629-34. PubMed ID: 20862579
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The effects of glycosaminoglycans on coagulation: a thromboelastographic study.
    Senzolo M; Coppell J; Cholongitas E; Riddell A; Triantos CK; Perry D; Burroughs AK
    Blood Coagul Fibrinolysis; 2007 Apr; 18(3):227-36. PubMed ID: 17413758
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients.
    Polkinghorne KR; McMahon LP; Becker GJ
    Am J Kidney Dis; 2002 Nov; 40(5):990-5. PubMed ID: 12407644
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Heparin-induced thrombocytopenia in paediatric patients--a review of the literature and a new case treated with danaparoid sodium.
    Ranze O; Ranze P; Magnani HN; Greinacher A
    Eur J Pediatr; 1999 Dec; 158 Suppl 3():S130-3. PubMed ID: 10650852
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Release of diamine oxidase into plasma by glycosaminoglycans in rats.
    D'Agostino L; Pignata S; Daniele B; Ventriglia R; Ferrari G; Ferraro C; Spagnuolo S; Lucchelli PE; Mazzacca G
    Biochim Biophys Acta; 1989 Dec; 993(2-3):228-32. PubMed ID: 2512987
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Danaparoid: a review of its use in thromboembolic and coagulation disorders.
    Ibbotson T; Perry CM
    Drugs; 2002; 62(15):2283-314. PubMed ID: 12381232
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Synopsis of the anticoagulant and antithrombotic profile of the low molecular weight heparinoid Org 10172 in experimental models.
    Meuleman DG
    Semin Thromb Hemost; 1989 Oct; 15(4):370-2. PubMed ID: 2479103
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Anticoagulation with recombinant hirudin following bone marrow transplantation in a patient with activated protein C resistance and heparin-induced antibodies showing cross-reactivity to the heparinoid danaparoid.
    Sauer M; Gruhn B; Fuchs D; Altermann WW; Greinacher A; Völpel H; Zintl F
    Med Pediatr Oncol; 1999 Jun; 32(6):457-8. PubMed ID: 10358710
    [No Abstract]   [Full Text] [Related]  

  • 53. Comparative study of Factor Xa fluorogenic substrates and their influence on the quantification of LMWHs.
    Castro-López V; Harris LF; O'Donnell JS; Killard AJ
    Anal Bioanal Chem; 2011 Jan; 399(2):691-700. PubMed ID: 20972772
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A review of 122 published outcomes of danaparoid anticoagulation for intermittent haemodialysis.
    Magnani HN
    Thromb Res; 2010 Apr; 125(4):e171-6. PubMed ID: 19926118
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Heparinoids with low anticoagulant potency attenuate postischemic endothelial cell dysfunction.
    Sternbergh WC; Sobel M; Makhoul RG
    J Vasc Surg; 1995 Mar; 21(3):477-83. PubMed ID: 7877230
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Multidisciplinary consultation for the prescription of danaparoid in suspected heparin-induced thrombocytopenia].
    Verdy E; Debrix I; Benomar A; Becker A; Flahault A
    Presse Med; 2007 May; 36(5 Pt 1):786-93. PubMed ID: 17303370
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Danaparoid in pregnancy in cases of heparin intolerance - use in 59 cases].
    Schindewolf M; Magnani HN; Lindhoff-Last E
    Hamostaseologie; 2007 May; 27(2):89-97. PubMed ID: 17479171
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dermatan sulfate and LMW heparin enhance the anticoagulant action of activated protein C.
    Fernández JA; Petäjä J; Griffin JH
    Thromb Haemost; 1999 Nov; 82(5):1462-8. PubMed ID: 10595639
    [TBL] [Abstract][Full Text] [Related]  

  • 59. New treatment options for heparin-induced thrombocytopenia.
    Ortel TL; Chong BH
    Semin Hematol; 1998 Oct; 35(4 Suppl 5):26-34; discussion 35-6. PubMed ID: 9855181
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anticoagulant mechanisms of Orgaran (Org 10172) and its fraction with high affinity to antithrombin III (Org 10849).
    Ofosu FA
    Haemostasis; 1992; 22(2):66-72. PubMed ID: 1379966
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.